14.04.2011 • News

Sanofi Weighing Options For U.S. Dermatology Unit

Sanofi-Aventis said it was considering "strategic alternatives" for its U.S. dermatology business, as it seeks to refocus its business on growth areas such as diabetes and cancer treatments.

The company's comment came after Bloomberg News published a story on Wednesday on how Sanofi was seeking to sell the unit, which the report said could be valued around €300 million.

Sanofi has said previously that its dermatology business could come under review because it was too small. It does not disclose sales for the unit.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Top-Feature

most read